Feeds:
Posts
Comments

Archive for the ‘Prostate prognosis’ Category

JULY 16: URO TODAY: Circulating tumour cells have been recently accepted by the US Food and Drug Administration  as a prognostic tool in advanced prostate cancer. However, a number of questions remain about the use of the test. READ MORE>

Read Full Post »

JULY 4: SCIENCE DAILY: Cancer experts at Johns Hopkins say a study tracking 774 prostate cancer patients for a median of eight years has shown that a three-way combination of measurements has the best chance yet of predicting disease metastasis. READ MORE>

The new prediction method comprises the length of time it takes for PSA (prostate-specific antigen) to double, Gleason score (a numeric indicator of prostate cancer aggressiveness as seen under the microscope), and the interval between surgical removal of the prostate and the first detectable PSA level.

According to Johns Hopkins investigators, combining these three measurements more accurately estimates risk that the cancer has spread than do other methods and should help determine which patients may benefit from additional therapy when PSA levels rise after surgery to remove the prostate.

Read Full Post »

JUNE 19: NEW PROSTATE CANCER INFOLINK: One of the major issues in the management of prostate cancer is the identification of early physical (as opposed to biochemical) evidence of metastatic disease. READ MORE>

Read Full Post »

JUNE 14: INSCIENCES: Prostate cancer patients and their doctors will have a better way of gauging long-term risks and pinpointing high risk cases with a new prostate cancer risk assessment test developed by a University of California San Francisco team. UCSF says the test proved accurate in predicting bone metastasis, prostate cancer-specific mortality, and all-cause mortality when localised prostate cancer is first diagnosed. The test is known as the UCSF Cancer of the Prostate Risk Assessment, or CAPRA. READ MORE>

Read Full Post »

JUNE 13: MODERN MEDICINE: The treatments for localised prostate cancer — prostatectomy, brachytherapy, and external radiation — have varied side effect profiles, and these should be taken into consideration in the selection of a treatment, according to a study published in the Journal of the National Cancer Institute. READ MORE>

Read Full Post »

JUNE 13: URO TODAY: WAVE3 is pivotal in controlling the invasiveness of prostate cancer cells, according to a new study at Cardiff University School of Medicine in the UK .

Wiskott-Aldrich syndrome verprolin-homologous 3 (WAVE3) belongs to Wiskott-Aldrich syndrome family proteins, which, along with other members, play a critical role in the regulation of actin polymerization and cell motility. We investigated the expression pattern and the effects of manipulating endogenous WAVE3 expression in prostate cancer cells.

Further work is needed to assess WAVE3 as a potential marker for predicting tumour aggressiveness. READ MORE>

Read Full Post »

JUNE 11: NEW PROSTATE CANCER INFO-LINK: It is well understood that skeletal complications are a crucial factor in the quality of life and the prognosis of patients with hormone-refractory prostate cancer; however, their true prevalence and impact on the prognosis remain largely unknown. READ MORE>

Read Full Post »

JUNE 9: URO TODAY: The mortality rate for prostate cancer is declining due to improvements in earlier detection and in local therapy strategies, but the ability to predict the metastatic behavior of a patient’s cancer, as well as to detect and eradicate disease recurrence remains some of the greatest clinical challenges in oncology. New research results demonstrate that advanced computational modelling can significantly improve the accuracy of molecular prognostic signatures for prostate cancer. READ MORE>

Read Full Post »

JUNE 6: URO TODAY:  Recent research indicates PSA can also be used to determine the risk of developing prostate cancer in the future. READ MORE>

Read Full Post »

JUNE 3: NEW PROSTATE CANCER INFO-LINK: New research shows that an undetectable PSA after radical prostatectomy is an indicator there is unlikely to be recurrence of cancer for at least five years. READ MORE>

Read Full Post »

« Newer Posts - Older Posts »